References

cardiotomsk

Сибирский журнал клинической и экспериментальной медицины

Siberian Journal of Clinical and Experimental Medicine

2713-29272713-265X

TSU publishing

10.29001/2073-8552-2016-31-3-16-22

cardiotomsk-222

Research Article

ОБЗОРЫ И ЛЕКЦИИ

REVIEWS AND LECTURES

СВЯЗЬ ПОЛИМОРФНЫХ ВАРИАНТОВ ГЕНОВ СЕРОТОНИНЭРГИЧЕСКОЙ СИСТЕМЫ С ДЕПРЕССИЕЙ И ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА (ОБЗОР ЛИТЕРАТУРЫ)

ASSOCIATION BETWEEN GENETIC POLYMORPHISMS WITHIN THE SEROTONERGIC SYSTEM, DEPRESSION AND CORONARY ARTERY DISEASE (REVIEW)

Лебедева

Н. Б.

Lebedeva

N. B.

докт. мед. наук, старший научный сотрудник лаборатории реабилитации, 650095, г. Кемерово, Сосновый бульвар, 6;

профессор кафедры подготовки врачей первичного звена здравоохранения, 650029, г. Кемерово, ул. Ворошилова, 22а

Kemerovo

lebenb@mail.ru

Ардашова

Н. Ю.

Ardashova

N. Y.

канд. мед. наук, научный сотрудник лаборатории реабилитации,

650095, г. Кемерово, Сосновый бульвар, 6

Kemerovo

ardashova_natali@mail.ru

Барбараш

О. Л.

Barbarash

O. L.

докт. мед. наук, профессор, член-корреспондент РАН, директор, 650095, г. Кемерово, Сосновый бульвар, 6;

заведующая кафедрой кардиологии и сердечно сосудистой хирургии, 650029, г. Кемерово, ул. Ворошилова, 22а

Kemerovo

olb61@mail.ru

Федеральное государственное бюджетное научное учреждение “Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний”; Государственное бюджетное образовательное учреждение высшего профессионального образования “Кемеровская государственная медицинская академия” Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Scientific Institution “Research Institute for Complex Issues of Cardiovascular Diseases”; Kemerovo State Medical AcademyRussian Federation

Федеральное государственное бюджетное научное учреждение “Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний”РоссияFederal State Budgetary Scientific Institution “Research Institute for Complex Issues of Cardiovascular Diseases”Russian Federation

2016

04112016

3131622

2016

Лебедева Н.Б., Ардашова Н.Ю., Барбараш О.Л.

Lebedeva N.B., Ardashova N.Y., Barbarash O.L.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.sibjcem.ru/jour/article/view/222

Изучение депрессии, коморбидной ишемической болезни сердца (ИБС) представляет большой интерес, что обусловлено высокой частотой ее возникновения и прогностической значимостью для исхода основного заболевания. В настоящее время биологические механизмы развития депрессии и ее связи с ИБС однозначно не определены, что связано с многообразием предрасполагающих и патогенетических факторов. В обзоре обсуждается роль полиморфизмов генов серотонинэргической системы в развитии депрессии, коморбидной ИБС.

The study of comorbid depression in patients with coronary artery disease (CAD) is pivotal since its high incidence and prognostic significance for the underlying disease. Currently, biological mechanisms of depression and its relationship with coronary artery disease are not clearly defined, which is associated with a variety of predisposing and pathogenetic factors. The review discusses the role of genetic polymorphisms within the serotonergic system in the development of comorbid depression in patients with coronary artery disease.

депрессияполиморфизм геновсеротонинэргическая системаишемическая болезнь сердца

depressiongenetic polymorphismsserotonergic systemcoronary artery disease

References1

Волель Б.А., Голимбет В.Е. Способ прогнозирования тяжести депрессивных расстройств у мужчин с ишемической болезнью сердца : патент на изобретение РФ № 2562557 от 10.09.2015; приоритет от 17.12.2013.

Голимбет В.Е., Украинцева С.В., Яшин А.И. Связь полиморфных вариантов гена переносчика серотонина с факторами, влияющими на физическое и психическое здоровье в процессе старения // Ж. неврологии и психиатрии им. Корсакова. – 2004. – № 5. – С. 46–49.

Лебедева Е.В., Гуткевич Е.В., Иванова С.А. и др. Феномен коморбидности депрессии и коронарной болезни в свете современных достижений генетики // Сибирский вестник психиатрии и наркол. – 2012. – Т. 75, № 6. – С. 41–47.

Мосолов С.Н. Современные биологические гипотезы рекуррентной депрессии (обзор) // Ж. неврологии и психиатрии. – 2012. – Т. 11(2). – С. 29–36.

Оганов Р.Г., Погосова Г.В., Колтунов И.Е. и др. Депрессивная симптоматика ухудшает прогноз сердечно-сосудистых заболеваний и снижает продолжительность жизни больных артериальной гипертонией и ишемической болезнью сердца // Кардиология. – 2011. – № 2. – C. 59–66.

Репин А.Н., Сергиенко Т.Н., Муслимова Э.Ф. и др. Влияние полиморфизма G681A гена CYP2C19 на эффективность клопидогрела при эндоваскулярном лечении ИБС в сочетании с сахарным диабетом 2 типа // Рос. кард. журн. – 2015. – № 10. – С. 81–85.

Спивак И.М. Генетическая связь креативности и психических заболеваний // Учен. записки СПбГМУ им. И.П. Павлова. – 2011. – Т. XVIII, № 4. – С. 11–14.

Смулевич А.Б. Депрессии при сердечно-сосудистых заболеваниях // Психич. расстройства в общей медицине. – 2013. – № 4. – С. 4–9.

Aumiller J. Depressive and sleepless: caution of myocardial infarct risk. Secondary risk factors // MMW Fortschr. Med. – 2009. – Vol. 14(20). – P. 18–19.

Aloyo V.J., Berg K.A., Spampinato U. et al. Current status of inverse agonismat serotonin 2° (2-HT2A) and 5-HT2Creceptors // Pharmacol. Ther. – 2009. – Vol. 121. – P. 160–173.

Adell A. LU AA.21004 a multimodal serotonergic agent for the potential treatment of depression and anxiety // I Drugs. – 2010. – Vol. 13. – P. 900–910.

Arnott S., Nutt D. Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine // British J. of Psychiatry. – 1994. – Vol. 164. – P. 838–839.

Blaya C., Salum G.A., Lima M.S. et al. Lack of association between the Serotonin Transporter Promoter Polymorphism (5-HTTLPR) and Panic Disorder: a systematic review and meta-analysis // Behav. Brain Funct. – 2007. – Vol. 18(3). – P. 41–44.

Carney R.M., Freedland K.E., Sheline Y.I. et al. Depression and coronary heart disease: a review for cardiologists // Clin. Cardiol. – 1997. – Vol. 20(3). – P. 196–200.

Cote F., Fligny C., Fromes Y. Recent advances in understanding serotonin regulation of cardiovascular function // Trends in Mol. Med. – 2004. – Vol. 10. – P. 232–238.

Coto E., Reguero J.R., Alvarez V. et al. 5-Hydroxytryptamine 5-HT2A receptor and 5-Hydroxytryptamine transporter polymorphism in acute myocardial infarction // Clin. Sci. (Lond). – 2003. – Vol. 104. – P. 241–245.

Caspi A., Sugden K., Moffitt T.E. et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene // Science. – 2003. – Vol. 301. – P. 386–389.

De Jonge P., van den Brink R.H., Spijkerman T. et al. Only incident depressive episodes after myocardial infarction are associated with new cardiovascular events // J. Am. Coll. Cardiol. – 2006. – Vol. 48. – P. 2204–2208.

Deakin J.F.W., Graeff F. 5-HT and mechanisms of defence // J. Psychopharmacol. – 1991. – Vol. 5. – P. 305–316.

Ford D.J., Kamerow D.B. Epidemiological study of sleep disturbances and psychiatric disorders // Am. J. Med. Assoc. – 1989. – Vol. 5. – P. 1479–1484.

Golimbet V.E., Volel B.A., Dolzhikov A.V. et al. Association of 5-HTR2A and 5-HTR2C serotonin receptor gene polymorphisms with depression risk in patient swith coronary heart disease // Bull. Exp. Biol. Med. – 2014. – Vol. 156(5). – P. 680–683.

Golimbet V.E., Lavrushina O.M., Kaleda V.G. et al. Supportive evidence for the association between the T102C 5-HTR2A gene polymorphism and schizophrenia: A large-scalecase control and family-based study // Eur. Psychiat. – 2007. – Vol. 22(3). – P. 167–170.

Grace S.L., Abbey S.E., Kapral M.K. et al. Effect of depression on five-year mortality after an acute coronary syndrome // Am. J. Cardiol. – 2005. – Vol. 96. – P. 1179–1185.

Harvey M., Shink E., Tremblay M. et al. Support for the involvement of TPH2 gene in affective disorders // Mol. Psychiatry. – 2004. – Vol. 9. – P. 980–981.

Heils A., Mobner R., Lesch K.P. The human serotonin transporter gene polymorphism basic research and clinical implications // J. of Neur. Transmission. – 1997. – Vol. 104. – P. 1005–1014.

Joynt K.E., O’Connor C.M. Lessons from STADHART, ENRICHD, and other trials // Psychosom. Med. – 2005. – Vol. 67 (Suppl. 1). – P. 63–66.

Karg K., Burmeister M., Shedden K. et al. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation // Arch. Gen. Psychiatry. – 2011. – Vol. 68(5). – P. 444–454.

Lee K.Y., Jeong S.H., Kim S.H. et al. Genetic Role of BDNF-Val66Met and 5-HTTLPR Polymorphisms on Depressive Disorder // Psychiatry Investig. – 2014. – Vol. 11(2). – P. 192–199.

Laposky A.D., Shelton J., Dugovic C. et al. Altered sleep regulation in leptin deficient mouse // Am. J. Phy. Regul. Integr. Comp. Physiol. – 2006. – Vol. 290. – P. 894–903.

Lemonde S., Turecki G., Bakish D. et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide // J. Neurosci. – 2003. – Vol. 23. – P. 8788–8789.

Lin J.Y., Jiang M.Y., Kan Z.M. et al. Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis // J. Affect. Disord. – 2014. – Vol. 168. – P. 430–438.

Lesch K.P., Greenberg B.D., Higley J.D. et al. Serotonin Transporter, Personality, And Behavior: Toward a Dissection of Gene-Gene and Gene-Environment Interaction. Molecular Genetics and the Human Personality. – Washington, DC : American Psychiatric Publishing, 2002. – P. 109–135.

Moffitt T.E., Brammer G.L., Caspi A. et al. Whole blood serotonin relates to violence in an epidemiological study // Biol. Psychiatry. – 1998. – Vol. 43(6). – P. 446–457.

Matsumoto Y., Fabbri C., Pellegrini S. et al. Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder // Mol. Diagn. Ther. – 2014. – Vol. 18(5). – P. 567–577.

Magnusson A., Partonen T. The diagnosis, symptomatology, and epidemiology of seasonal affective disorder // CNSS pectr. – 2005. – Vol. 10. – P. 625–634.

Mцssner R., Walitza S., Geller F. et al. Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase 2 gene in children and adolescents with obsessive compulsive disorder // Int. J. Neuropsychopharmacol. – 2006. – Vol. 9. – P. 437–442.

Maron E., Toru I., Must A. et al. Association study of tryptophan hydroxylase 2 gene polymorphisms in panic disorder // Neurosci. Lett. – 2007. – Vol. 411(3). – P. 180–184.

Murphy D.L., Lerner A., Rudnick G. et al. Serotonin transporter: gene, genetic disorders, and pharmacogenetics // Mol. Interv. – 2004. – Vol. 4(2). – P. 109–123.

Maron E., Tasa G., Toru I. et al. Association between serotonin-related genetic polymorphisms and CCK 4-induced panic attacks with or without 5-hydroxytryptophan pretreatment in healthy volunteers // World J. Biol. Psychiatry. – 2004. – Vol. 5(3). – P. 149–154.

Maron E., Nikopensius T., Koks S. et al. Association study of 90 candidate gene polymorphisms in panic disorder // Psychiatr. Genet. – 2005. – Vol. 15(1). – P. 17–24.

Otte C., McCaffery J., Ali S. et al. Association of a serotonin transporter polymorphism (5-HTTLPR) with depression, perceived stress, and norepinephrine in patients with coronary disease: the Heart and Soul Study // Am. J. Psychiatry. – 2007. – Vol. 164. – P. 1379–1384.

Parker G.B., Hilton T.M., Walsh W.F. et al. Timing is everything: the onset of depression and acute coronary syndrome outcome // Biol. Psychiatry. – 2008. – Vol. 64(8). – P. 660–666.

Phillips Bute В., Mathew J.P, Blumenthal J.A. et al. Perioperative genetics and safety outcomes investigative team. Relationship of genetic variability and depressive symptoms to adverse events after coronary artery bypass graft Surgery // Psychosom. Med. – 2008. – Vol. 70(9). – P. 953–959.

Partonen T., Reutlein J., Alpman A. et al. Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter depression // Ann. Med. – 2005. – Vol. 39. – P. 229–238.

Pitchot W., Hansenne M., Pinto E. et al. 5-Hydroxytryptamine 1 Areceptors, major depression, and suicidal behavior // Biol. Psychiatry. – 2005. – Vol. 58. – P. 854–858.

Polesskaya O.O., Sokolov B.P. Differential expression of the “C” and “T” alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics // J. Neurosci. Res. – 2002. – Vol. 67. – P. 812–822.

Pezawas L., Meyer Lindenberg A., Drabant E.M. et al. 5-HTTLPR polymorphism impacts human cingulate amygdalainteractions: a genetics usceptibility mechanism for depression // Nat. Neurosci. – 2005. – Vol. 8. – P. 828–834.

Perna G., Favaron E., Di Bella D. et al. Anti-panic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene // Neuropsychopharmacology. – 2005. – Vol. 30(12). – P. 2230–2235.

Puri V.K., Verma M., Saxena A.K. et al. Platelet serotonergic mechanisms in ischemic heart disease // Thromb. Res. – 1990. – Vol. 57. – P. 445–451.

Rothman R.B., Ayestas M.A., Dersch C.M. et al. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension // Circulation. – 1999. – Vol. 100(8). – P. 869–875.

Ripke S., Wray N.R., Lewis C.M. et al. A mega-analysis of genome-wide association studies for major depressive disorder. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium // Mol. Psychiatry. – 2013. – Vol. 18(4). – P. 497–511.

Rothe C., Gutknecht L., Freitag C. et al. Association of a functional 1019C>G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia // Int. J. Neuropsychopharmacol. – 2004. – Vol. 7. – P. 189–192.

Ramage A.G. Central cardiovascular regulation and 5-hydroxytryptamine receptors // Brain Res. Bull. – 2001. – Vol. 56. – P. 425–439.

Sullivan P.F., Neale M.C., Kendler K.S. Genetic epidemiology of major depression: review and meta analysis // Am. J. Psychiatry. – 2000. – Vol. 157. – P. 1552–1562.

Simeonova D.I., Chang K.D., Strong C. et al. Creativity in familial bipolar disorder // J. Psychiatr. Res. – 2005. – Vol. 39(6). – P. 623–631.

Strobel A., Gutknecht L., Rothe C. et al. Allelic variation in 5-HT1A receptor expression is associated with anxiety and depression-related personality traits // J. Neural. Transmission. – 2003. – Vol. 110. – P. 1445–1453.

Sheehan K., Lowe N., Kirley A. et al. Tryptophan hydroxylase 2-(TPH2) gene variants associated with ADHD // Mol. Psychiatry. – 2005. – Vol. 10. – P. 944–949.

Sabol S.Z., Hu S., Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter // Hum. Genet. – 1998. – Vol. 103(3). – P. 273–279.

Syagailo Y.V., Stober G., Grassle M. et al. Association analysis of the functional monoamine oxidase A gene promoter polymorphism in psychiatric disorders // Am. Med. Genet. – 2001. – Vol. 105(2). – P. 168–171.

Schulze T.G., Muller D.J., Krauss H. et al. Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder // Am. J. Med. Genet. – 2000. – Vol. 96. – P. 801–803.

Varcoe T.J., Kennaway D.J. Activation of 5-HT2C receptors acutely induces Perl gene expression in the rat SCN in vitro // Brain Res. – 2008. – Vol. 1209. – P. 19–28.

Walther D.J., Peter J.U., Bashammakh S. et al. Synthesis of serotonin by a second thryptophan hydroxylase isoform // Science. – 2003. – Vol. 299. – P. 76–79.

Yamada S., Akita H., Kanazawa K. et al. T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute myocardial infarction // Atherosclerosis. – 2000. – Vol. 150(1). – P. 143–148.

Zhao X., Sun L., Sun Y.H. et al. Association of HTR2A T102C and A-1438G polymorphisms with susceptibility to major depressive disorder: a meta-analysis // Acta Psychiatr. Scand. – 2014. – Vol. 35(12). – P. 1857–1866.

Zhang X., Gainetdinov R.R., Beaulieu J.M. et al. Loss of function mutation in tryptophan hydroxylase 2 identified in unipolar major depression // Neuron. – 2005. – Vol. 45. – P. 11–16.

Zhou Z., Roy A., Lipsky R. et al. Haplotype based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations // Arch. Gen. Psychiatry. – 2005. – Vol. 62. – Р. 1109–1118.

The authors declare that there are no conflicts of interest present.